Protalix BioTherapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $3.8M | $18.3M | $2.4M | $164.0K | $-3.6M | $3.2M | $-2.2M | $-4.6M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | $404.0K | — | — | $346.0K | — | — | $322.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | $532.0K | — | — | $540.0K | — | — | $981.0K |
| Net Cash from Operating Activities | $-10.4M | $22.0M | $-3.7M | $-5.2M | $-5.1M | $4.1M | $-3.6M | $4.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $593.0K | $761.0K | $498.0K | $431.0K | $306.0K | $87.0K | $172.0K | $598.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $4.2M | — | — | $-312.0K | — | — | $-606.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $150.0K | — | — | $5.1M | — | — | — |
| Net Change in Cash | — | $26.3M | — | — | $-302.0K | — | — | $3.6M |
| Free Cash Flow | $-11.0M | $21.3M | $-4.2M | $-5.7M | $-5.4M | $4.0M | $-3.8M | $3.6M |